Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines

AIM: We aim to determine the cost‐effectiveness of dapagliflozin in addition to standard therapy versus standard therapy alone among patients with heart failure with reduced ejection fraction (HFrEF) using the public healthcare provider's perspective in the Philippines. METHODS AND RESULTS: A t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendoza, Victor L., Tumanan‐Mendoza, Bernadette A., Punzalan, Felix Eduardo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712807/
https://www.ncbi.nlm.nih.gov/pubmed/34494399
http://dx.doi.org/10.1002/ehf2.13583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712807/
https://www.ncbi.nlm.nih.gov/pubmed/34494399
http://dx.doi.org/10.1002/ehf2.13583

Ejemplares similares